Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Abstract PO1-04-14: PLK1 Inhibitor Onvansertib Extends the Response and Overcomes Resistance to Paclitaxel in Palbociclib-resistant HR+ Breast Cancer Patient-derived Xenografts

Maya Ridinger, Pierre Painsec, Sreeja Sreekumar, Dalia Gonzalez, Davis Klein, Laura Sourd, Elodie Montaudon, Paul Cottu, Tod Smeal, Elisabetta Marangoni

Cancer Res (2024) 84 (9_Supplement): PO1-04-14.

https://doi.org/10.1158/1538-7445.SABCS23-PO1-04-14

Published: 02 May 2024

View article titled, Abstract PO1-04-14: PLK1 Inhibitor Onvansertib Extends the Response and Overcomes Resistance to Paclitaxel in Palbociclib-resistant HR+ Breast Cancer Patient-derived Xenografts

Journal Articles

Abstract PO2-04-09: Combination of the PLK1 Inhibitor Onvansertib and the PI3Kα Inhibitor Alpelisib Overcomes Palbociclib Resistance in PIK3CA-mutated HR+ Breast Cancer

Sreeja Sreekumar, Pierre Painsec, Davis Klein, Dalia Gonzalez, Laura Sourd, Elodie Montaudon, Tod Smeal, Elisabetta Marangoni, Maya Ridinger

Cancer Res (2024) 84 (9_Supplement): PO2-04-09.

https://doi.org/10.1158/1538-7445.SABCS23-PO2-04-09

Published: 02 May 2024

View article titled, Abstract PO2-04-09: Combination of the PLK1 Inhibitor Onvansertib and the PI3Kα Inhibitor Alpelisib Overcomes Palbociclib Resistance in PIK3CA-mutated HR+ Breast Cancer

Journal Articles

Abstract PO4-23-10: Restoring the efficacy of standard of care in treatment-refractory ER+ breast cancer by re-activation of cAMP-ROS-DNA damage axis

Ozge Saatci, Metin Cetin, Meral Uner, Unal Metin Tokat, Ioulia Chatzistamou, Pelin Gulizar Ersan, Elodie Montaudon, Aytekin Akyol, Sercan Aksoy, Aysegul Uner, Elisabetta Marangoni, Sajish Mathew, Ozgur Sahin

Cancer Res (2024) 84 (9_Supplement): PO4-23-10.

https://doi.org/10.1158/1538-7445.SABCS23-PO4-23-10

Published: 02 May 2024

View article titled, Abstract PO4-23-10: Restoring the efficacy of standard of care in treatment-refractory ER+ breast cancer by re-activation of cAMP-ROS-DNA damage axis

Journal Articles

Abstract 4661: A dual degrader of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models

Lu Yang, Arup Bhattacharya, Darrell Peterson, Yun Li, Xiaozhuo Liu, Elisabetta Marangoni, Valentina Robila, Yuesheng Zhang

Cancer Res (2024) 84 (6_Supplement): 4661.

https://doi.org/10.1158/1538-7445.AM2024-4661

Published: 22 March 2024

View article titled, Abstract 4661: A dual degrader of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models

Journal Articles

Abstract 563: Targeting PDE4D reinstates toxic PARP trapping via cAMP-ROS-DNA damage axis and restores the efficacy of standard of care in treatment-refractory ER+ breast cancer

Ozge Saatci, Metin Cetin, Meral Uner, Unal M. Tokat, Ioulia Chatzistamou, Elodie Montaudon, Aytekin Akyol, Sercan Aksoy, Aysegul Uner, Elisabetta Marangoni, Mathew Sajish, Ozgur Sahin

Cancer Res (2024) 84 (6_Supplement): 563.

https://doi.org/10.1158/1538-7445.AM2024-563

Published: 22 March 2024

View article titled, Abstract 563: Targeting PDE4D reinstates toxic PARP trapping via cAMP-ROS-DNA damage axis and restores the efficacy of standard of care in treatment-refractory ER+ breast cancer

Journal Articles

Abstract A008: Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer

Ozge Saatci, Mein Cetin, Meral Uner, Unal Metin Tokat, Ioulia Chatzistamou, Pelin Gulizar Ersan, Elodie Montaudon, Aytekin Akyol, Sercan Aksoy, Aysegul Uner, Elisabetta Marangoni, Mathew Sajish, Ozgur Sahin

Cancer Res (2024) 84 (1_Supplement): A008.

https://doi.org/10.1158/1538-7445.DNAREPAIR24-A008

Published: 09 January 2024

View article titled, Abstract A008: Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer

Journal Articles

Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER⁺ Breast Cancers

Arany Soosainathan, Marjan Iravani, Rania El-Botty, John Alexander, Laura Sourd, Ludivine Morisset, Pierre Painsec, Rebecca Orha, Joanna Nikitorowicz-Buniak, Sunil Pancholi, Syed Haider, Mitch Dowsett, Elisabetta Marangoni, Lesley-Ann Martin, Clare M. Isacke

Cancer Res (2024) 84 (1): 17–25.

https://doi.org/10.1158/0008-5472.CAN-23-0650

Published: 02 January 2024

View article titled, Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers

Includes: Supplementary data

Journal Articles

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER⁺ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

Cancer Res (2023) 83 (23): 3989–4004.

https://doi.org/10.1158/0008-5472.CAN-23-0694

Published: 01 December 2023

View article titled, The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

Includes: Supplementary data

Journal Articles

Abstract 3883: Overcoming tamoxifen resistance by re-activating cAMP-Ca²⁺⁻ROS-ferroptosis axis in ER+ breast cancer

Rashedul Alam, Ozge Saatci, Meral Bugadyci Uner, Kim-Tuyen Huynh-Dam, Metin Cetin, Mustafa Emre Gedik, Nevin Belder, Hilal Bal, Unal Metin Tokat, Elisabetta Marangoni, Sercan Aksoy, Aysegul Uner, Aytekin Akyol, Ozgur Sahin

Cancer Res (2023) 83 (7_Supplement): 3883.

https://doi.org/10.1158/1538-7445.AM2023-3883

Published: 04 April 2023

View article titled, Abstract 3883: Overcoming tamoxifen resistance by re-activating cAMP-Ca2+−ROS-ferroptosis axis in ER+ breast cancer

Journal Articles

Abstract 4677: A preclinical platform of breast cancer PDX and derived cellular models as a tool for pharmacological screening and functional studies

Delphine Nicolle, Aurore Gorce, Marie Tavernier, Elisabetta Marangoni, Didier Decaudin, Christophe Ginestier, Emmanuelle Charafe-Jaufret, Judith Passildas, Nina Robin, Robert Clarke, Erwan Corcuff, Anaïs Joachim, Bernard Malissen, Ana Zarubica, Hervé Luche, Jean-Gabriel Judde, Olivier Déas

Cancer Res (2023) 83 (7_Supplement): 4677.

https://doi.org/10.1158/1538-7445.AM2023-4677

Published: 04 April 2023

View article titled, Abstract 4677: A preclinical platform of breast cancer PDX and derived cellular models as a tool for pharmacological screening and functional studies

Journal Articles

Abstract 649: Targeting progesterone receptor (PR) with the antiprogestin onapristone in patient-derived xenograft (PDX) models of estrogen receptor positive (ER+), PR positive (PR+) bone metastasis of breast cancer

Martin Lehr, Ahmed Dahmani, Léa Huguet, Rania El-Botty, Charlène Thiebaut, Muriel Romancer, Paul Cottu, Elisabetta Marangoni

Cancer Res (2022) 82 (12_Supplement): 649.

https://doi.org/10.1158/1538-7445.AM2022-649

Published: 15 June 2022

View article titled, Abstract 649: Targeting progesterone receptor (PR) with the antiprogestin onapristone in patient-derived xenograft (PDX) models of estrogen receptor positive (ER+), PR positive (PR+) bone metastasis of breast cancer

Journal Articles

Abstract 3984: GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers

Cancer Res (2022) 82 (12_Supplement): 3984.

https://doi.org/10.1158/1538-7445.AM2022-3984

Published: 15 June 2022

View article titled, Abstract 3984: GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers

Journal Articles

Abstract PD9-07: Mdm2 gene amplification in estrogen receptor-positive breast cancer cells is associated with enhanced solid tumor growth and pronounced metastatic potential in humanized tumor mice (HTM) and a poor outcome of patients with luminal breast cancer

Anja Kathrin Wege, Valentina Vladimirova, Christine Solbach, Eva-Maria Rom-Jurek, Jens-Uwe Blohmer, Paul Jank, Bruno Sinn, Andreas Trumpp, Elisabetta Marangoni, Knut Engels, Wilko Weichert, Nicole Pfarr, Christoph Irlbeck, Bernhard Polzer, Olaf Ortmann, Marion van Mackelenbergh, Carsten Denkert, Sibylle Loibl, Gero Brockhoff

Cancer Res (2022) 82 (4_Supplement): PD9-07.

https://doi.org/10.1158/1538-7445.SABCS21-PD9-07

Published: 15 February 2022

View article titled, Abstract PD9-07: Mdm2 gene amplification in estrogen receptor-positive breast cancer cells is associated with enhanced solid tumor growth and pronounced metastatic potential in humanized tumor mice (HTM) and a poor outcome of patients with luminal breast cancer

Journal Articles

YAP and β-Catenin Cooperate to Drive Oncogenesis in Basal Breast Cancer

Hazel M. Quinn, Regina Vogel, Oliver Popp, Philipp Mertins, Linxiang Lan, Clemens Messerschmidt, Alexandro Landshammer, Kamil Lisek, Sophie Château-Joubert, Elisabetta Marangoni, Elle Koren, Yaron Fuchs, Walter Birchmeier

Cancer Res (2021) 81 (8): 2116–2127.

https://doi.org/10.1158/0008-5472.CAN-20-2801

Published: 15 April 2021

View article titled, YAP and β-Catenin Cooperate to Drive Oncogenesis in Basal Breast Cancer

Includes: Supplementary data

Journal Articles

Abstract 1685: The EurOPDX Research Infrastructure: Supporting European and worldwide cancer research with patient-derived xenografts

Cancer Res (2020) 80 (16_Supplement): 1685.

https://doi.org/10.1158/1538-7445.AM2020-1685

Published: 15 August 2020

View article titled, Abstract 1685: The EurOPDX Research Infrastructure: Supporting European and worldwide cancer research with patient-derived xenografts

Journal Articles

Abstract 3182: Kindlin-1 expression is associated with EGFR/RAS/MAPK activation and response to MEK inhibitors in triple-negative breast cancer

Paula Azorin, Florian Bonin, Zakia Tariq, Florence Coussy, Elisabetta Marangoni, Rosette Lidereau, Keltouma Driouch

Cancer Res (2020) 80 (16_Supplement): 3182.

https://doi.org/10.1158/1538-7445.AM2020-3182

Published: 15 August 2020

View article titled, Abstract 3182: Kindlin-1 expression is associated with EGFR/RAS/MAPK activation and response to MEK inhibitors in triple-negative breast cancer

Journal Articles

Abstract 1118: Absence of mouse-specific tumor evolution in patient-derived cancer xenografts

Cancer Res (2020) 80 (16_Supplement): 1118.

https://doi.org/10.1158/1538-7445.AM2020-1118

Published: 15 August 2020

View article titled, Abstract 1118: Absence of mouse-specific tumor evolution in patient-derived cancer xenografts

Journal Articles

Abstract 5313: TT-00420, a novel multiple kinase inhibitor to treat TNBC

Peng Peng, Guoyu Li, Xiaoyan Qiang, Yuwei Tian, Qi Yu, Elisabetta Marangoni, Frank Wu

Cancer Res (2020) 80 (16_Supplement): 5313.

https://doi.org/10.1158/1538-7445.AM2020-5313

Published: 15 August 2020

View article titled, Abstract 5313: TT-00420, a novel multiple kinase inhibitor to treat TNBC

Journal Articles

Abstract 925: PDX models of ER+ endocrine-resistant metastatic breast cancer identify Polo-like kinase 1 (PLK1) as a therapeutic target

Cancer Res (2019) 79 (13_Supplement): 925.

https://doi.org/10.1158/1538-7445.AM2019-925

Published: 01 July 2019

View article titled, Abstract 925: PDX models of ER+ endocrine-resistant metastatic breast cancer identify Polo-like kinase 1 (PLK1) as a therapeutic target

Journal Articles

Abstract 2973: A comprehensive panel of patient-derived xenografts representing the molecular heterogeneity and diversity of triple-negative breast cancer

Florence Coussy, Virginie Bernard, Marion Lavigne, Anais Boulai, Sophie Chateau-Joubert, Ahmed Dahmani, Elodie Montaudon, Cécile Reyes, Rania El Botty, Gaëlle Pieron, Cécile Laurent, Samia Melaabi, Anne Vincent Salomon, Ivan Bièche, Elisabetta Marangoni

Cancer Res (2018) 78 (13_Supplement): 2973.

https://doi.org/10.1158/1538-7445.AM2018-2973

Published: 01 July 2018

View article titled, Abstract 2973: A comprehensive panel of patient-derived xenografts representing the molecular heterogeneity and diversity of triple-negative breast cancer

NARROW

Abstract PO1-04-14: PLK1 Inhibitor Onvansertib Extends the Response and Overcomes Resistance to Paclitaxel in Palbociclib-resistant HR+ Breast Cancer Patient-derived Xenografts

Abstract PO2-04-09: Combination of the PLK1 Inhibitor Onvansertib and the PI3Kα Inhibitor Alpelisib Overcomes Palbociclib Resistance in PIK3CA-mutated HR+ Breast Cancer

Abstract PO4-23-10: Restoring the efficacy of standard of care in treatment-refractory ER+ breast cancer by re-activation of cAMP-ROS-DNA damage axis

Abstract 4661: A dual degrader of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models

Abstract 563: Targeting PDE4D reinstates toxic PARP trapping via cAMP-ROS-DNA damage axis and restores the efficacy of standard of care in treatment-refractory ER+ breast cancer

Abstract A008: Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer

Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER⁺ Breast Cancers

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER⁺ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

Abstract 3883: Overcoming tamoxifen resistance by re-activating cAMP-Ca²⁺⁻ROS-ferroptosis axis in ER+ breast cancer

Abstract 4677: A preclinical platform of breast cancer PDX and derived cellular models as a tool for pharmacological screening and functional studies

Abstract 649: Targeting progesterone receptor (PR) with the antiprogestin onapristone in patient-derived xenograft (PDX) models of estrogen receptor positive (ER+), PR positive (PR+) bone metastasis of breast cancer

Abstract 3984: GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers

Abstract PD9-07: Mdm2 gene amplification in estrogen receptor-positive breast cancer cells is associated with enhanced solid tumor growth and pronounced metastatic potential in humanized tumor mice (HTM) and a poor outcome of patients with luminal breast cancer

YAP and β-Catenin Cooperate to Drive Oncogenesis in Basal Breast Cancer

Abstract 1685: The EurOPDX Research Infrastructure: Supporting European and worldwide cancer research with patient-derived xenografts

Abstract 3182: Kindlin-1 expression is associated with EGFR/RAS/MAPK activation and response to MEK inhibitors in triple-negative breast cancer

Abstract 1118: Absence of mouse-specific tumor evolution in patient-derived cancer xenografts

Abstract 5313: TT-00420, a novel multiple kinase inhibitor to treat TNBC

Abstract 925: PDX models of ER+ endocrine-resistant metastatic breast cancer identify Polo-like kinase 1 (PLK1) as a therapeutic target

Abstract 2973: A comprehensive panel of patient-derived xenografts representing the molecular heterogeneity and diversity of triple-negative breast cancer

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only